(Q38237895)

31 August 2017

title

Posaconazole salvage treatment for invasive fungal infection (English)

1 reference

invasive fungal infections

31 August 2017

main subject

1 reference

Jong Hun Kim

1

1 reference

31 August 2017

Kali Williams

series ordinal

2

1 reference

31 August 2017

publication date

8 August 2014

1 reference

31 August 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Mycopathologia

1 reference

31 August 2017

volume

178

1 reference

31 August 2017

issue

3-4

1 reference

31 August 2017

page(s)

259-265

1 reference

https://scigraph.springernature.com/pub.10.1007/s11046-014-9792-y

31 August 2017

exact match

0 references

cites work

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Epidemiology of fungal infections in solid organ transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Emerging fungal infections in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Global estimates of the prevalence of diabetes for 2010 and 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

A multicenter, open-label study of posaconazole oral suspension in the treatment of invasive fungal infections in patients refractory to or intolerant of first-line therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Posaconazole treatment in Korea: single-center experience over 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

21 January 2018

How I treat mucormycosis

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11046-014-9792-Y

Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25103141

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Epidemiology and treatment approaches in management of invasive fungal infections

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25103141

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11046-014-9792-Y

1 reference

Dimensions Publication ID

31 August 2017

1002714210

0 references

1 reference